By Clinical Research News Staff 

July 12, 2022 | Worldwide Clinical Trials and Invitae have announced a strategic partnership. Worldwide will be the first CRO to use Invitae’s Explorer tool, part of its real-world data platform that enables access to aggregated genetic testing results. 

Through this partnership, Worldwide has access to data insights based on prevalence, incidence, demographics, geography, and epidemiology for rare disease patients. This aggregated data enables Worldwide to recruit patients faster and pinpoint optimal study locations to help its sponsors uncover new and potentially life-saving treatments for people suffering from rare diseases. 

“This is a game-changer for both our sponsors and patients enrolled in clinical trials,” said Peter Benton, President and Co-CEO, Worldwide, in a press release. “Our unique access to Invitae’s database provides us with superior visibility to an aggregate-level view of patients we otherwise wouldn’t be aware of and enables us to offer advanced clinical trial strategies to our sponsors. This also helps us boost much-needed patient recruitment efforts, expanding our reach and ability to connect the right patients with the right clinical trial opportunities.” 

“Our strategic collaboration enables Worldwide to gain valuable insight into the genetic etiology of rare disease to help shape and improve the future of clinical trials,” said Sean George, Ph.D., Co-Founder and CEO of Invitae in the same press release. “Our cutting-edge tools empower Worldwide with the opportunity to set clinical trial strategies based on specific disease and geographic prevalence to yield the data needed to treat genetic disorders globally.” 

With access to Invitae’s aggregated genetic testing data, Worldwide has enhanced its capability to combat the complexities of rare disease trials through quicker visibility of where patients are, with the ultimate goal of providing well-deserved and meaningful treatments.